China Pharmaceutical Excipients Industry Report, 2014-2017
  • Nov.2014
  • Hard Copy
  • USD $2,500
  • Pages:101
  • Single User License
    (PDF Unprintable)       
  • USD $2,300
  • Code: ZLC011
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,600
  • Hard Copy + Single User License
  • USD $2,700
      

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China’s gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

Currently, pharmaceutical excipients account for about 2%-3% of China's total output value of pharmaceutical preparations. Chinese pharmaceutical excipient market size reached about RMB26.35 billion in 2013 and is expected to be RMB54.83 billion in 2017.

There are about 400 pharmaceutical excipient manufacturers in China, of which over 90 ones or 23% specialize in the production of pharmaceutical excipients, while most of the remaining ones focus on chemical or food processing.

Currently, foreign leading pharmaceutical excipient companies, such as Colorcon (the USA), Degussa (Germany), Meggle (Germany) and Roquette (France), have set up joint ventures, wholly-owned companies or offices in China. Colorcon mainly provides film-coated products; Meggle pharmaceutical lactose, and Roquette pharmaceutical starch and polyols.

Chinese pharmaceutical excipient giants include Er-Kang Pharmaceutical, Sunhere Pharmaceutical Excipients, Dongbao Bio-Tech, Qinghai Gelatin, Shandong Liaocheng A Hua Pharmaceutical, Zhanwang Pharmaceutical and Qufu Tianli, but their market concentration rate is rather low. As a tycoon, Er-Kang Pharmaceutical only seized about 2.7% market share in 2013.

Ranking among the largest Chinese pharmaceutical excipient producers with the most complete types, Er-Kang Pharmaceutical holds 116 types of pharmaceutical excipients and the capacity of 45,000 tons or more. Over the past two years, the company has continued to enforce epitaxial expansion strategy and accelerate market layout. In March 2014, the company acquired 100% stake in Changsha Zhengyang Pharmaceutical Capsule and 51% stake in Hunan Dongting Citric Acid Chemicals. In addition, the company’s 180,000 tons/a medicinal cassava starch production project went into operation on March 31, 2014; the first phase of "South China Pharmaceutical Excipient Base Construction Project" has been completed and will realize production goal at the end of 2014.
?
Sunhere Pharmaceutical Excipients is a Chinese member of International Pharmaceutical Excipient Confederation (IPEC), mainly producing microcrystalline cellulose, hydroxypropyl cellulose, hypromellose and other 18 types of new-type pharmaceutical excipients with the capacity of 10,000 tons. On April 24, 2014, Sunhere Pharmaceutical Excipients planned to go public so as to raise funds for 7,100 tons/a new-type pharmaceutical excipient production line expansion project.

Zhanwang Pharmaceutical produces 28 types of pharmaceutical excipient products including carboxymethyl starch sodium, pre-gelatinized starch, hypromellose, microcrystalline cellulose, etc., with the capacity of over 10,000 tons. Some production bases of the company have passed the certification of the US FDA and the European COS. Now, export has contributed 25% to the company’s revenue.

药用辅料 英文_副本.png

The report includes the following aspects:
20120114.gifOperating environment (including economy, policies, barriers to entry, upstream and downstream environment) of China pharmaceutical excipient industry;
20120114.gifStatus quo, competition pattern, import & export and development trend of China pharmaceutical excipient industry;
20120114.gifOperation, pharmaceutical excipient business and prospects of 10 major Chinese pharmaceutical excipient companies;
20120114.gifDevelopment forecast and operation comparison between major enterprises in China pharmaceutical excipient industry.

1 Overview of Pharmaceutical Excipients
1.1 Overview
1.2 Classification

2 Operating Environment of China Pharmaceutical Excipient Industry
2.1 Economy
2.2 Policies
2.3 Entry Barriers
2.3.1 Qualification
2.3.2 R & D and Technology
2.3.3 Marketing Channels and Brands
2.3.4 Funds
2.4 Upstream and Downstream Environment
2.4.1 Upstream
2.4.2 Downstream

3 Development of China Pharmaceutical Excipient Industry
3.1 International Market
3.2 Status Quo
3.3 Competition Pattern
3.4 Import and Export
3.4.1 Import
3.4.2 Export
3.5 Breakdown Products
3.5.1 Pharmaceutical Gelatin
3.5.2 Hydroxypropyl Methyl Cellulose (HPMC)
3.5.3 Pharmaceutical Starch
3.5.4 Pharmaceutical Sucrose
3.5.5 Propanediol
3.6 Development Trend
3.6.1 Marketing Channels and Brand Building Are Strengthened
3.6.2 The Industry Heads toward Production Specialization and Standardization   
3.6.3 The Varieties of Pharmaceutical Excipients Increase 
3.6.4 Downstream Pharmaceutical Preparation Industry Boosts Pharmaceutical Excipient Industry
3.6.5 Industrial Concentration Rate Will Ascend Gradually
3.6.6 Technological Development Turns the Focus to Security, Functionality, Adaptability, Efficiency, etc.  
3.6.7 Composite Excipients Will Be One Development Direction of Pharmaceutical Excipients

4 Major Companies
4.1 Er-Kang Pharmaceutical  
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 Gross Margin  
4.1.5 R & D and Investment 
4.1.6 Pharmaceutical Excipient Business 
4.1.7 Forecast and Outlook 
4.2 Sunhere Pharmaceutical Excipients   
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin  
4.2.5 R & D and Investment 
4.2.6 Output and Sales Volume 
4.2.7 Supply 
4.2.8 Forecast and Outlook 
4.3 Dongbao Bio-Tech   
4.3.1 Profile 
4.3.2 Revenue 
4.3.3 Revenue Structure 
4.3.4 Gross Margin  
4.3.5 R & D and Investment 
4.3.6 Pharmaceutical Excipient Business 
4.3.7 Forecast and Outlook 
4.4 Qinghai Gelatin 
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Gross Margin  
4.4.5 Pharmaceutical Excipient Business 
4.4.6 Forecast and Outlook 
4.5 Shandong Head 
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin  
4.5.5 R & D and Investment 
4.5.6 Pharmaceutical Excipient Business 
4.5.7 Output and Sales Volume 
4.5.8 Supply 
4.5.9 Forecast and Outlook 
4.6 Shandong Liaocheng A Hua Pharmaceutical
4.6.1 Profile 
4.6.2 Operation 
4.6.3 Pharmaceutical Excipient Business 
4.7 Zhanwang Pharmaceutical 
4.7.1 Profile 
4.7.2 Operation 
4.7.3 Pharmaceutical Excipient Business 
4.8 Qufu Tianli 
4.8.1 Profile 
4.8.2 Pharmaceutical Excipient Business 
4.9 North China Pharmaceutical 
4.9.1 Profile 
4.9.2 Operation 
4.9.3 Revenue Structure 
4.9.4 Pharmaceutical Excipient Business 
4.10 Joinway Pharmaceutical 
4.10.1 Profile 
4.10.2 Pharmaceutical Excipient Business

5 Forecast and Outlook 
5.1 Industrial Development Forecast 
5.2 Operation Comparison between Major Enterprises
5.2.1 Revenue 
5.2.2 Net Profit 
5.2.3 Net Profit Margin 
5.2.4 Gross Margin  
5.2.5 Pharmaceutical Excipient Business 
Classification of Pharmaceutical Excipients   
China's GDP and YoY Growth Rate, 1985-2014 
Policies and Regulations on China Pharmaceutical Excipient Industry 
China’s Corn Starch Output, 2009-2013
China’s Corn Starch Price, Oct-Nov 2014 
China’s Refined Cotton Price, Dec 2013-Apr 2014
China’s Chemical Preparation Manufacturing Revenue and YoY Growth, 2009-2013    
China’s Chinese Patent Medicine Manufacturing Revenue and YoY Growth, 2009-2013 
China’s Biological and Biochemical Manufacturing Revenue and YoY Growth, 2009-2013
China’s Pharmaceutical Excipient Market Size, 2009-2014
Structure of Chinese Pharmaceutical Excipient Enterprises (by Type)
Market Share of Major Chinese Pharmaceutical Excipient Companies, 2013
Products, Categories and Capacity of Major Chinese Pharmaceutical Excipient Companies, 2013
Top 10 Gelatin Capsule Import Sources of China by Import Volume and Value, 2013-2014
Top 10 Gelatin Capsule Export Destinations of China by Export Volume and Value, 2013-2014
Gelatin Consumption Structure (%) by Country / Region
China’s Gelatin Output Structure (by Type)
China’s Gelatin and Bone Gelatin Market Capacity, 2005-2014
China’s MC/HPMC Capacity, 2006-2013
China’s Pharmaceutical Cellulose Ether Demand, 2009-2016E
China’s Starch Output, 2009-2013
Proportion of China’s Starch Output (by Product)
China’s Starch Import and Export (by Product), 2013
China’s Medicinal Starch Quality Index
China’s Medicinal Starch Demand, 2011-2015E
China’s Sugar Output and YoY Growth Rate, 2006/07-2013/14  
Output Proportion of China's Main Sugar Producing Areas, 2013-2014
Quality Index Comparison between Medicinal Sucrose and White Sugar
China’s Propanediol Output and YoY Growth, 2005-2010     
China’s Propanediol Import and Export, Jan-Sep 2014
Revenue and Net Income of Er-Kang Pharmaceutical, 2009-2014
Revenue of Er-Kang Pharmaceutical (by Product), 2009-2014
Revenue Structure of Er-Kang Pharmaceutical (by Product), 2009-2014
Revenue of Er-Kang Pharmaceutical (by Region), 2009-2014
Revenue Structure of Er-Kang Pharmaceutical (by Region), 2009-2014
Gross Margin of Er-Kang Pharmaceutical, 2009-2014
Gross Margin of Er-Kang Pharmaceutical (by Product), 2009-2014
R & D Costs and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2013
Completion of Fund-raising Projects of Er-Kang Pharmaceutical, 2013
Pharmaceutical Excipient Revenue and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2014
Main Pharmaceutical Excipient Capacity of Er-Kang Pharmaceutical, 2013
Revenue and Net Income of Er-Kang Pharmaceutical, 2012-2017E
Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2011-2013
Revenue of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
Revenue Structure of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
Revenue of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
Revenue Structure of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
Gross Margin of Sunhere Pharmaceutical Excipients, 2011-2013
R & D Costs and % of Total Revenue of Sunhere Pharmaceutical Excipients, 2011-2013
Fund-raising Projects of Sunhere Pharmaceutical Excipients and Allocation of Raised Funds
Capacity, Capacity Utilization and Sales-Output Ratio of Main Products of Sunhere Pharmaceutical Excipients, 2011-2013
Top Five Customers of Sunhere Pharmaceutical Excipients in Basic Raw Material Products, 2011-2013
Top Five Customers of Sunhere Pharmaceutical Excipients in Crude-product Fine Processing Products, 2011-2013
Top Five Suppliers of Sunhere Pharmaceutical Excipients in Basic Raw Material Production, 2011-2013
Top Five Suppliers of Sunhere Pharmaceutical Excipients in Excellent-product Fine Processing and Production, 2011-2013
Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2012-2017E 
Revenue and Net Income of Dongbao Bio-Tech, 2010-2014
Revenue of Dongbao Bio-Tech (by Product), 2010-2014
Revenue of Dongbao Bio-Tech (by Region), 2011-2014
Revenue Structure of Dongbao Bio-Tech (by Region), 2011-2014
Gross Margin of Dongbao Bio-Tech, 2011-2014
Gross Margin of Dongbao Bio-Tech (by Product), 2011-2014
Gross Margin of Dongbao Bio-Tech (by Region), 2011-2013
R & D Costs and % of Total Revenue of Dongbao Bio-Tech, 2011-2013
Completion of Fund-raising Projects of Dongbao Bio-Tech, 2013
Pharmaceutical Gelatin Revenue of Dongbao Bio-Tech, 2010-H1 2014
Revenue and Net Income of Dongbao Bio-Tech, 2012-2017E 
Revenue and Net Income of Qinghai Gelatin, 2010-2014
Revenue of Qinghai Gelatin (by Product), 2010-2014
Revenue of Qinghai Gelatin (by Sector), 2010-2014
Revenue of Qinghai Gelatin (by Region), 2011-2014
Revenue Structure of Qinghai Gelatin (by Region), 2011-2014
Gross Margin of Qinghai Gelatin, 2010-2014
Gross Margin of Qinghai Gelatin (by Product), 2010-2014
Gross Margin of Qinghai Gelatin (by Region), 2012-2014
Pharmaceutical Excipient Revenue and% of Total Revenue of Qinghai Gelatin, 2010-2014
Revenue and Net Income of Qinghai Gelatin, 2012-2017E
Classification and Properties of Cellulose Ether
Revenue and Net Income of Shandong Head, 2011-2013
Revenue of Shandong Head (by Product), 2011-2013
Revenue Structure of Shandong Head (by Product), 2011-2013
Revenue of Shandong Head (by Region), 2011-2013
Revenue Structure of Shandong Head (by Region), 2011-2013
Domestic Revenue of Shandong Head (by Region), 2011-2013
Overseas Revenue of Shandong Head (by Region), 2011-2013
Gross Margin of Shandong Head, 2011-2013
Gross Margin of Shandong Head (by Product), 2011-2013
R & D Costs and % of Total Revenue of Shandong Head, 2011-2013
Fund-raising Projects of Shandong Head and Allocation of Raised Funds
Pharmaceutical Excipient Revenue, % of Total Revenue and Gross Margin of Shandong Head, 2011-2013
Capacity, Output and Sales Volume of Main Products of Shandong Head, 2011-2013
Diacetone Acrylamide Capacity, Output and Sales Volume of Shandong Head, 2011-2013
Top Five Customers of Shandong Head, 2011-2013
Top Five Suppliers of Shandong Head, 2011-2013
Revenue and Net Income of Shandong Head, 2012-2017E 
Total Assets, Revenue and Net Income of Shandong Liaocheng A Hua Pharmaceutical, 2010-2014
Capacity and Application of Main Products of Shandong Liaocheng A Hua Pharmaceutical
Revenue of Zhanwang Pharmaceutical, 2012-2016E
Capacity of Main Pharmaceutical Excipient Products of Qufu Tianli
Revenue and Net Income of North China Pharmaceutical, 2009-2014
Revenue of North China Pharmaceutical (by Product), 2009-2014
Revenue Structure of North China Pharmaceutical (by Product), 2009-2014
Revenue of North China Pharmaceutical (by Region), 2009-2014
Revenue Structure of North China Pharmaceutical (by Region), 2009-2014 
Chinese Pharmaceutical Excipient Market Size, 2012-2017E
Revenue of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Net Income of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Net Profit Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Gross Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Pharmaceutical Excipient Revenue of Major Chinese Pharmaceutical Excipient Companies, 2009-2013

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统